IL1B and cancer: Consequently, treatment of cells with the anti-cancer drug and DPP8/9 active site inhibitor talabostat (Val-boroPro, PT-100) [119] induces NLRP1 activation in human keratinocytes and the downstream secretion of high levels of IL-1β [48,120].